In LMICs, the availability of medicines manufactured locally that do not meet quality standards is a leading cause of treatment failure and adverse events in patients and is undermining public health interventions. But where do things go wrong during pharmaceutical manufacturing in LMICs that give rise to this problem? Learn more.
Today, we join the global health community in marking World Malaria Day. As we reflect on the major strides being made against this deadly disease, we also recognize that critical obstacles remain.
On this World Malaria Day, the world is calling for an end to malaria. We must increase efforts to ensure that antimalarials used to treat malaria are safe, effective and of good-quality. Here are some ways we can close the treatment gap and provide the millions of people newly infected with malaria each year with reliable, quality-assured medicines.
Learn about USP's involvement in the APEC Life Sciences Innovation Forum and how this group is improving access to quality medical products by helping Asian-Pacific economies prevent, detect and respond to spurious, substandard, falsified, falsely-labelled and counterfeit products in their supply chains.
Poor quality medicines are the source of an alarming, but often overlooked global health crisis. A report from the International Policy Network estimates that 700,000 people die every year from fake anti-malarial and tuberculosis drugs alone.
Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) marked a major milestone in the fight against substandard and poor quality drugs by acheiving internationally recognized ISO 17025 accreditation.
Access to quality care and medicines is an integral part of public health. For USP, an organization that creates and promotes public standards for medicines and foods, quality and access are two sides of the same coin and in fact the absence of either one actually threatens effectiveness of medical care around the world.
In Liberia, sellers of poor-quality medicines are capitalizing on public fears about Ebola. Learn what the Liberia Medicines and Health Products Regulatory Authority is doing about it and how the Promoting the Quality of Medicines Program--a collaborative effort between USAID and USP--is playing a role.